FAK inhibitor and drug combination thereof
US12194040B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 24, 2019 |
| Grant date | Jan 14, 2025 |
| Priority date | — |
| Expiry date | Nov 22, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A deuterated compound as represented by formula (I) or an optical isomer, a tautomer, a pharmaceutically acceptable salt, a prodrug, a hydrate, or a solvate thereof are presented. Compared with a compound before deuteration, the deuterated compound shows better pharmacokinetics, higher maximum plasma drug concentration, higher exposure, and longer half-life, and has more excellent metabolic performance. The deuterated compound can effectively inhibit FAK activity, and has good application prospect in preparation of FAK inhibitors and/or drugs for treating cancer. In addition, the use of the deuterated compound in combination with an anti-cancer drug (such as a PD-1 inhibitor) can achieve a synergistic effect, thereby significantly improving the tumor suppression effect, and providing a better choice for clinical cancer treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.